Volume 67, Issue 1, Pages (July 2017)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Volume 54, Issue 1, Pages (January 2011)
Volume 60, Issue 1, Pages (January 2014)
Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity  Paula Walle, Markus Takkunen, Ville Männistö, Maija Vaittinen,
High-protein diets prevent steatosis and induce hepatic accumulation of monomethyl branched-chain fatty acids  Sonia C. Garcia Caraballo, Tine M. Comhair,
Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome  M. Miriam Jacome-Sosa, Faye.
Volume 63, Issue 1, Pages (July 2015)
Role of thyroid hormone homeostasis in obesity-prone and obesity-resistant mice fed a high-fat diet  Shu-Fang Xia, Xiao-Mei Duan, Li-Yue Hao, Li-Ting.
Volume 67, Issue 1, Pages (July 2017)
Volume 139, Issue 6, Pages e1 (December 2010)
Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study  Jacob J. Christensen,
Altered hepatic lipid status and apolipoprotein A-I metabolism in mice lacking phospholipid transfer protein  Sarah Siggins, Igor Bykov, Martin Hermansson,
Inflammasomes in liver diseases
Go Woon Kim, Hee Kyung Jo, Sung Hyun Chung  Journal of Ginseng Research 
Volume 63, Issue 2, Pages (August 2015)
A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,
Volume 65, Issue 6, Pages (December 2016)
Volume 67, Issue 2, Pages (August 2017)
Won Hee Choi, Jiyun Ahn, Chang Hwa Jung, Jung Sook Seo, Tae Youl Ha 
Volume 63, Issue 4, Pages (October 2015)
Inhibition of Sebum Production with the Acetyl Coenzyme A Carboxylase Inhibitor Olumacostat Glasaretil  David W. Hunt, Geoffrey C. Winters, Roger W. Brownsey,
A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 15, Issue 1, Pages (January 2012)
Volume 24, Issue 3, Pages (July 2018)
Won Hee Choi, Jiyun Ahn, Chang Hwa Jung, Jung Sook Seo, Tae Youl Ha 
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,
Volume 42, Issue 5, Pages (May 2005)
The Double Life of Irs Cell Metabolism
ChREBP in NASH – A liver transcription factor comes in from the cold
Volume 42, Issue 6, Pages (June 2005)
Volume 44, Issue 4, Pages (April 2006)
Volume 22, Issue 5, Pages (November 2015)
Volume 53, Issue 5, Pages (November 2010)
Volume 62, Issue 1, Pages (January 2015)
Amalia Gastaldelli, Giulio Marchesini  Journal of Hepatology 
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Thiazolidinediones Regulate Adipose Lineage Dynamics
Volume 12, Issue 2, Pages (August 2010)
Volume 9, Issue 6, Pages (June 2009)
Volume 103, Issue 12, Pages (December 2012)
Volume 18, Issue 13, Pages (March 2017)
EASL Clinical Practice Guidelines: Wilson’s disease
Nobuhiko Takahashi, Yong Qi, Hiral R. Patel, Rexford S. Ahima 
Sizing up Surfactant Synthesis
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 16, Issue 4, Pages (October 2012)
Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.
Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology 
Volume 62, Issue 6, Pages (June 2015)
Volume 10, Issue 5, Pages (November 2009)
Volume 19, Issue 2, Pages (February 2014)
Volume 3, Issue 2, Pages (February 2006)
Volume 64, Issue 6, Pages (June 2016)
Changes in the 24-h plasma cortisol rhythm in patients with cirrhosis
Volume 67, Issue 5, Pages (November 2017)
Volume 66, Issue 1, Pages (January 2017)
Volume 63, Issue 1, Pages (July 2015)
Volume 134, Issue 6, Pages (September 2008)
HCV animal models and liver disease
John G. Purdy, Thomas Shenk, Joshua D. Rabinowitz  Cell Reports 
Volume 16, Issue 4, Pages (October 2012)
Volume 139, Issue 6, Pages e1 (December 2010)
Pathogenesis of cholestatic hepatitis C
Volume 26, Issue 4, Pages e4 (January 2019)
Genetics of hepatocellular carcinoma: The next generation
Bill Andriopoulos, Kostas Pantopoulos  Journal of Hepatology 
Shih-Yen Weng, Detlef Schuppan  Journal of Hepatology 
Tomonobu Ezure, Satoshi Amano  Journal of Investigative Dermatology 
Volume 66, Issue 1, Pages (July 2004)
Presentation transcript:

Volume 67, Issue 1, Pages 128-136 (July 2017) Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD  Panu K. Luukkonen, You Zhou, Nidhina Haridas P.A. , Om P. Dwivedi, Tuulia Hyötyläinen, Ashfaq Ali, Anne Juuti, Marja Leivonen, Taru Tukiainen, Linda Ahonen, Emma Scott, Jeremy M. Palmer, Johanna Arola, Marju Orho-Melander, Petter Vikman, Quentin M. Anstee, Vesa M. Olkkonen, Matej Orešič, Leif Groop, Hannele Yki-Järvinen  Journal of Hepatology  Volume 67, Issue 1, Pages 128-136 (July 2017) DOI: 10.1016/j.jhep.2017.02.014 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Clinical characteristics of the groups based on the TM6SF2 genotype. BMI, fasting serum insulin, liver fat, serum adiponectin, plasma glucose concentrations during OGTT and serum insulin concentrations during OGTT. Light blue bars, black circles and solid lines, TM6SF2EE (n=80). Dark blue bars, open circles and broken lines, TM6SF2EK/KK (n=10). Data are in means±SEM or median (25th-75th percentile); Student’s t test and Mann-Whitney U test, as appropriate; *p<0.05. Journal of Hepatology 2017 67, 128-136DOI: (10.1016/j.jhep.2017.02.014) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Fold-change of hepatic triglycerides (TG) in the TM6SF2EK/KK group compared to the TM6SF2EE group. The color key shows the log of the ratio between means of the groups of an individual TG. The brighter the red color, the greater increase of absolute concentration of the individual TG in the TM6SF2EK/KK compared to the TM6SF2EE group. The y-axis denotes the number of carbons and the x-axis the number of double bonds. Student’s t test; *p<0.05. Journal of Hepatology 2017 67, 128-136DOI: (10.1016/j.jhep.2017.02.014) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 3 In vitro experiments. (A) TM6SF2 mRNA expression in control shRNA (shNT) and TM6SF2 shRNA (shTM6SF2) expressing HuH-7 cells. The experiment was run twice in triplicates. (B) Staining of lipid droplets by BODIPY® 493/503 in shNT and shTM6SF2 expressing HuH-7 cells and (C) the quantification of lipid droplet area per cell. The data represent the average of 150 cells from each set. The relative incorporation of [3H]-palmitic acid, [3H]-oleic acid and [3H]-arachidonic acid into triglycerides (D), cholesteryl esters (E) and phosphatidylcholines (F) expressed in percentage relative to control (n=5). Data are shown as mean±SD; Student’s t test; *p<0.05, **p<0.01, ***p<0.001. Journal of Hepatology 2017 67, 128-136DOI: (10.1016/j.jhep.2017.02.014) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Differences in hepatic cholesteryl esters (CE), phosphatidylcholines (PC) and free fatty acids (FFA) between the groups. Concentrations of total and individual liver CEs (top left panel) and total liver PCs (top right panel) in TM6SF2EK/KK relative to TM6SF2EE group. The height of the bars represent% lipid concentration in TM6SF2EK/KK relative to TM6SF2EE group. Linear regression between the number of double bonds (middle left panel) and carbons (middle right panel) in PCs and fold-change of liver PCs in the TM6SF2EK/KK vs. the TM6SF2EE group (solid line). The intercepts and slopes denote deviation of this regression line from 0. Each circle denotes a different lipid. Concentrations of different liver FFA (bottom left panel) and liver FFA as a percentage of total (bottom right panel) in TM6SF2EK/KK and TM6SF2EE. Data are in means±SEM or median (25th–75th percentile); Student’s t test and Mann-Whitney U test, as appropriate; *p<0.05, **p<0.01. Journal of Hepatology 2017 67, 128-136DOI: (10.1016/j.jhep.2017.02.014) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 5 Fold-change in serum triglycerides (TGs), phosphatidylcholines (PCs) and cholesteryl esters (CEs) in the TM6SF2EK/KK group compared to the TM6SF2EE group. Linear regression between the number of double bonds (left panels) and carbons (right panels) in serum TGs (top), PCs (middle), and CEs (bottom) and fold-change of respective serum lipids in the TM6SF2EK/KK vs. the TM6SF2EE group (solid line). The intercepts and slopes denote deviation of this regression line from 0. Each circle denotes a different lipid. Journal of Hepatology 2017 67, 128-136DOI: (10.1016/j.jhep.2017.02.014) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 6 Hepatic lipid-related gene expression pathways enriched with genes co-expressing with TM6SF2. Names of the pathways are in bold and names of the genes in italics. Blue color denotes genes correlating positively (i.e. decreasing in TM6SF2 E167K carriers) and red color those correlating negatively with the expression of TM6SF2. Bold italics denote genes regulated by polyunsaturated fatty acids.41,42,52–55 Journal of Hepatology 2017 67, 128-136DOI: (10.1016/j.jhep.2017.02.014) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 7 Summary of changes in hepatic polyunsaturated fatty acid (PUFA) metabolism in vivo in TM6SF2 E167K gene variant carriers, and in vitro in TM6SF2 knockout HuH-7 cells. The percentage of hepatic free 20:4 fatty acid (FA) is increased in vivo. First step in synthesis of cholesteryl esters (CE), triglycerides (TG), and phosphatidylcholines (PC) is activation of free fatty acids into acyl-coenzyme A (CoA). These acyl-CoAs are esterified with cholesterol to form CEs. The in vitro incorporation of 20:4 into CEs is decreased, and concentrations of serum polyunsaturated CE are decreased in vivo. Acyl-CoAs are also utilized in de novo synthesis (via synthesis of lysophosphatidic acid, phosphatidic acid and diacylglycerol) of TGs and PCs. Incorporation of 20:4 into TGs and PCs is decreased in vitro, and hepatic concentrations of polyunsaturated TGs and PCs are decreased in vivo. Hepatic gene expression in vivo is characterized by changes in the expression of genes regulated by free PUFA. In summary, these in vivo and in vitro findings suggest that hepatic lipid synthesis from PUFA is impaired in TM6SF2 E167K gene variant carriers. Journal of Hepatology 2017 67, 128-136DOI: (10.1016/j.jhep.2017.02.014) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2017 67, 128-136DOI: (10. 1016/j. jhep. 2017. 02 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions